Cholesterol, inflammation and innate immunity

Nature Reviews Immunology

Volumn 15, Issue 2, 2015, Pages 104-116

  Tall, Alan R ^a   Yvan Charvet, Laurent ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; INFLAMMASOME; TOLL LIKE RECEPTOR;

CHOLESTEROL TRANSPORT; HUMAN; INFLAMMATION; INFLAMMATORY CELL; INNATE IMMUNITY; MACROPHAGE; MONOCYTE; MONOCYTOSIS; MYELOPOIESIS; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; IMMUNOLOGY; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; CHOLESTEROL; HUMANS; IMMUNITY, INNATE; INFLAMMATION; MACROPHAGES;

EID: 84923046255     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3793     Document Type: Review

References (143)

1. Moore, K. J. & Tabas, I. Macrophages in the pathogenesis of atherosclerosis. Cell 145, 341-355 (2011).
2. Stewart, C. R. et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nature Immunol. 11, 155-161 (2010).
3. Yvan-Charvet, L. et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J. Clin. Invest. 117, 3900-3908 (2007).
4. Yvan-Charvet, L. et al. Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation 118, 1837-1847 (2008).
5. Fessler, M. B. & Parks, J. S. Intracellular lipid flux and membrane microdomains as organizing principles in inflammatory cell signaling. J. Immunol. 187, 1529-1535 (2011).
6. Zhu, X. et al. Macrophage ABCA1 reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol. J. Lipid Res. 51, 3196-3206 (2010).
7. Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357-1361 (2010).
8. Sheedy, F. J. et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nature Immunol. 14, 812-820 (2013).
9. Tall, A. R., Yvan-Charvet, L., Terasaka, N., Pagler, T. & Wang, N. H. D. L. ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell. Metab. 7, 365-375 (2008).
10. Rader, D. J. & Tall, A. R. The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis? Nature Med. 18, 1344-1346 (2012).
11. Castrillo, A. et al. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol. Cell 12, 805-816 (2003).
12. Feingold, K. R. & Grunfeld, C. The acute phase response inhibits reverse cholesterol transport. J. Lipid Res. 51, 682-684 (2010).
13. Post, W. S. et al. Associations between HIV infection and subclinical coronary atherosclerosis. Ann. Intern. Med. 160, 458-467 (2014).
14. + count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 355, 2283-2296 (2006).
15. Sherer, Y. & Shoenfeld, Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nature Clin. Pract. Rheumatol. 2, 99-106 (2006).
16. Vandanmagsar, B. et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nature Med. 17, 179-188 (2011).
17. Stienstra, R. et al. Inflammasome is a central player in the induction of obesity and insulin resistance. Proc. Natl Acad. Sci. USA 108, 15324-15329 (2011).
18. Umemoto, T. et al. Apolipoprotein AI and high-density lipoprotein have anti-inflammatory effects on adipocytes via cholesterol transporters: ATP-binding cassette A-1, ATP-binding cassette G-1, and scavenger receptor B-1. Circ. Res. 112, 1345-1354 (2013).
19. Chung, S. et al. Dietary cholesterol promotes adipocyte hypertrophy and adipose tissue inflammation in visceral, but not in subcutaneous, fat in monkeys. Arterioscler. Thromb. Vasc. Biol. 34, 1880-1887 (2014).
20. Norata, G. D., Pirillo, A., Ammirati, E. & Catapano, A. L. Emerging role of high density lipoproteins as a player in the immune system. Atherosclerosis 220, 11-21 (2012).
21. Ronda, N. et al. Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. Ann. Rheum. Dis. 73, 609-615 (2014).
22. Rosenson, R. S. et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 125, 1905-1919 (2012).
23. Wang, X. et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J. Clin. Invest. 117, 2216-2224 (2007).
24. Wang, N., Lan, D., Chen, W., Matsuura, F. & Tall, A. R. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc. Natl Acad. Sci. USA 101, 9774-9779 (2004).
25. Rader, D. J., Alexander, E. T., Weibel, G. L., Billheimer, J. & Rothblat, G. H. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J. Lipid Res. 50, S189-S194 (2009).
26. Martel, C. et al. Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice. J. Clin. Invest. 123, 1571-1579 (2013).
27. Lim, H. Y. et al. Lymphatic vessels are essential for the removal of cholesterol from peripheral tissues by SR-BI-mediated transport of HDL. Cell. Metab. 17, 671-684 (2013).
28. Acton, S. et al. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271, 518-520 (1996).
29. Inazu, A. et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N. Engl. J. Med. 323, 1234-1238 (1990).
30. Yu, L. et al. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J. Clin. Invest. 110, 671-680 (2002).
31. Zhao, G. J. et al. Antagonism of betulinic acid on LPS-mediated inhibition of ABCA1 and cholesterol efflux through inhibiting nuclear factor-κB signaling pathway and miR-33 expression. PLoS ONE 8, e74782 (2013).
32. Masucci-Magoulas, L. et al. Decreased cholesteryl ester transfer protein (CETP) mRNA and protein and increased high density lipoprotein following lipopolysaccharide administration in human CETP transgenic mice. J. Clin. Invest. 95, 1587-1594 (1995).
33. McGillicuddy, F. C. et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation 119, 1135-1145 (2009).
34. Pajkrt, D. et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J. Exp. Med. 184, 1601-1608 (1996).
35. Harris, H. W., Gosnell, J. E. & Kumwenda, Z. L. The lipemia of sepsis: triglyceride-rich lipoproteins as agents of innate immunity. J. Endotoxin Res. 6, 421-430 (2000).
36. Van Lenten, B. J. et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest. 96, 2758-2767 (1995).
37. Watson, A. D. et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96, 2882-2891 (1995).
38. 2. J. Lipid Res. 51, 743-754 (2010).
39. de la Llera Moya, M. et al. Inflammation modulates human HDL composition and function in vivo. Atherosclerosis 222, 390-394 (2012).
40. Bergt, C. et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc. Natl Acad. Sci. USA 101, 13032-13037 (2004).
41. Zheng, L. et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest. 114, 529-541 (2004).
42. McMillen, T. S., Heinecke, J. W. & LeBoeuf, R. C. Expression of human myeloperoxidase by macrophages promotes atherosclerosis in mice. Circulation 111, 2798-2804 (2005).
43. Hewing, B. et al. Effects of native and myeloperoxidase-modified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 34, 779-789 (2014).
44. Shao, B. et al. Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase. Circ. Res. 114, 1733-1742 (2014).
45. Huang, Y. et al. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nature Med. 20, 193-203 (2014).
46. Zhu, X. et al. Myeloid cell-specific ABCA1 deletion protects mice from bacterial infection. Circ. Res. 111, 1398-1409 (2012).
47. Brown, M. S. & Goldstein, J. L. Suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and inhibition of growth of human fibroblasts by 7-ketocholesterol. J. Biol. Chem. 249, 7306-7314 (1974).
48. Chen, H. W., Kandutsch, A. A. & Waymouth, C. Inhibition of cell growth by oxygenated derivatives of cholesterol. Nature 251, 419-421 (1974).
49. Beigneux, A. P., Moser, A. H., Shigenaga, J. K., Grunfeld, C. & Feingold, K. R. The acute phase response is associated with retinoid X receptor repression in rodent liver. J. Biol. Chem. 275, 16390-16399 (2000).
50. Bjorkbacka, H. et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nature Med. 10, 416-421 (2004).
51. Mullick, A. E., Tobias, P. S. & Curtiss, L. K. Modulation of atherosclerosis in mice by Toll-like receptor 2. J. Clin. Invest. 115, 3149-3156 (2005).
52. Mullick, A. E. et al. Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events. J. Exp. Med. 205, 373-383 (2008).
53. Feig, J. E. et al. HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells. Proc. Natl Acad. Sci. USA 108, 7166-7171 (2011).
54. Monaco, C. et al. Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. Circulation 120, 2462-2469 (2009).
55. Zhu, X. et al. Increased cellular free cholesterol in macrophage-specific Abca1-knock-out mice enhances pro-inflammatory response of macrophages. J. Biol. Chem. 283, 22930-22941 (2008).
56. Westerterp, M. et al. Deficiency of ATP-binding cassette transporters A1 and G1 in macrophages increases inflammation and accelerates atherosclerosis in mice. Circ. Res. 112, 1456-1465 (2013).
57. Spann, N. J. et al. Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses. Cell 151, 138-152 (2012).
58. Yang, C. et al. Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J. Biol. Chem. 281, 27816-27826 (2006).
59. Triantafilou, M., Miyake, K., Golenbock, D. T. & Triantafilou, K. Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J. Cell Sci. 115, 2603-2611 (2002).
60. Pagler, T. A. et al. Deletion of ABCA1 and ABCG1 impairs macrophage migration because of increased Rac1 signaling. Circ. Res. 108, 194-200 (2011).
61. Li, H. B., Jin, C., Chen, Y. & Flavell, R. A. Inflammasome activation and metabolic disease progression. Cytokine Growth Factor Rev. 25, 699-706 (2014).
62. Razani, B. et al. Autophagy links inflammasomes to atherosclerotic progression. Cell. Metab. 15, 534-544 (2012).
63. Nakahira, K. et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nature Immunol. 12, 222-230 (2011).
64. Shi, C. S. et al. Activation of autophagy by inflammatory signals limits IL-1β production by targeting ubiquitinated inflammasomes for destruction. Nature Immunol. 13, 255-263 (2012).
65. Ouimet, M. et al. Autophagy regulates cholesterol efflux from macrophage foam cells via lysosomal acid lipase. Cell. Metab. 13, 655-667 (2011).
66. Sheedy, F. J. & Moore, K. J. IL-1 signaling in atherosclerosis: sibling rivalry. Nature Immunol. 14, 1030-1032 (2013).
67. Blankenberg, S. et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 106, 24-30 (2002).
68. -/- mice through release of interferon-γ. Circ. Res. 90, e34-e38 (2002).
69. Mallat, Z. et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ. Res. 89, e41-e45 (2001).
70. Menu, P. et al. Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasome. Cell Death Dis. 2, e137 (2011).
71. Usui, F. et al. Critical role of caspase-1 in vascular inflammation and development of atherosclerosis in Western diet-fed apolipoprotein E-deficient mice. Biochem. Biophys. Res. Commun. 425, 162-168 (2012).
72. Gage, J., Hasu, M., Thabet, M. & Whitman, S. C. Caspase-1 deficiency decreases atherosclerosis in apolipoprotein E-null mice. Can. J. Cardiol 28, 222-229 (2012).
73. Zheng, F., Xing, S., Gong, Z., Mu, W. & Xing, Q. Silence of NLRP3 suppresses atherosclerosis and stabilizes plaques in apolipoprotein E-deficient mice. Mediators Inflamm. 2014, 507208 (2014).
74. Small, D. M. & Shipley, G. G. Physical-chemical basis of lipid deposition in atherosclerosis. Science 185, 222-229 (1974).
75. Small, D. M. George Lyman Duff memorial lecture. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry. Arteriosclerosis 8, 103-129 (1988).
76. Kellner-Weibel, G. et al. Crystallization of free cholesterol in model macrophage foam cells. Arterioscler Thromb. Vasc. Biol. 19, 1891-1898 (1999).
77. Tangirala, R. K. et al. Formation of cholesterol monohydrate crystals in macrophage-derived foam cells. J. Lipid Res. 35, 93-104 (1994).
78. McDonald, J. G. & Russell, D. W. Editorial: 25-Hydroxycholesterol: a new life in immunology. J. Leukoc. Biol. 88, 1071-1072 (2010).
79. Diczfalusy, U. et al. Marked upregulation of cholesterol 25-hydroxylase expression by lipopolysaccharide. J. Lipid Res. 50, 2258-2264 (2009).
80. Park, K. & Scott, A. L. Cholesterol 25-hydroxylase production by dendritic cells and macrophages is regulated by type I interferons. J. Leukoc. Biol. 88, 1081-1087 (2010).
81. Liu, S. Y. et al. Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity 38, 92-105 (2013).
82. Gold, E. S. et al. 25-Hydroxycholesterol acts as an amplifier of inflammatory signaling. Proc. Natl Acad. Sci. USA 111, 10666-10671 (2014).
83. Reboldi, A. et al. Inflammation. 25-Hydroxycholesterol suppresses interleukin-1-driven inflammation downstream of type I interferon. Science 345, 679-684 (2014).
84. Gurcel, L., Abrami, L., Girardin, S., Tschopp, J. & van der Goot, F. G. Caspase-1 activation of lipid metabolic pathways in response to bacterial pore-forming toxins promotes cell survival. Cell 126, 1135-1145 (2006).
85. Xiao, H. et al. Sterol regulatory element binding protein 2 activation of NLRP3 inflammasome in endothelium mediates hemodynamic-induced atherosclerosis susceptibility. Circulation 128, 632-642 (2013).
86. Choi, J. H. et al. Flt3 signaling-dependent dendritic cells protect against atherosclerosis. Immunity 35, 819-831 (2011).
87. Randolph, G. J. Mechanisms that regulate macrophage burden in atherosclerosis. Circ. Res. 114, 1757-1771 (2014).
88. Li, P. et al. NCoR repression of LXRs restricts macrophage biosynthesis of insulin-sensitizing omega 3 fatty acids. Cell 155, 200-214 (2013).
89. Serhan, C. N. Pro-resolving lipid mediators are leads for resolution physiology. Nature 510, 92-101 (2014).
90. Rong, X. et al. LXRs regulate ER stress and inflammation through dynamic modulation of membrane phospholipid composition. Cell. Metab. 18, 685-697 (2013).
91. Ghisletti, S. et al. Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARγ. Mol. Cell 25, 57-70 (2007).
92. N., A. G. et al. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 31, 245-258 (2009).
93. Gerbod-Giannone, M. C. et al. TNFα induces ABCA1 through NF-κB in macrophages and in phagocytes ingesting apoptotic cells. Proc. Natl Acad. Sci. USA 103, 3112-3117 (2006).
94. Murphy, A. J. et al. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J. Clin. Invest. 121, 4138-4149 (2011).
95. Coller, B. S. Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene? Arterioscler. Thromb. Vasc. Biol. 25, 658-670 (2005).
96. Swirski, F. K. & Nahrendorf, M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 339, 161-166 (2013).
97. Yvan-Charvet, L. et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 328, 1689-1693 (2010).
98. Gao, M. et al. Regulation of high-density lipoprotein on hematopoietic stem/progenitor cells in atherosclerosis requires scavenger receptor type BI expression. Arterioscler. Thromb. Vasc. Biol. 34, 1900-1909 (2014).
99. Tolani, S. et al. Hypercholesterolemia and reduced HDL-C promote hematopoietic stem cell proliferation and monocytosis: studies in mice and FH children. Atherosclerosis 229, 79-85 (2013).
100. Feng, Y. et al. Hematopoietic stem/progenitor cell proliferation and differentiation is differentially regulated by high-density and low-density lipoproteins in mice. PLoS ONE 7, e47286 (2012).
101. Wang, M. et al. Interleukin-3/granulocyte macrophage colony-stimulating factor receptor promotes stem cell expansion, monocytosis, and atheroma macrophage burden in mice with hematopoietic ApoE deficiency. Arterioscler. Thromb. Vasc. Biol. 34, 976-984 (2014).
102. van Kampen, E., Jaminon, A., van Berkel, T. J. & Van Eck, M. Diet-induced (epigenetic) changes in bone marrow augment atherosclerosis. J. Leukoc. Biol. 96, 833-841 (2014).
103. Westerterp, M. et al. Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways. Cell Stem Cell 11, 195-206 (2012).
104. Hong, C. et al. Coordinate regulation of neutrophil homeostasis by liver X receptors in mice. J. Clin. Invest. 122, 337-347 (2012).
105. high monocytes that infiltrate atherosclerotic lesions. Circulation 125, 364-374 (2012).
106. Rauch, P. J. et al. Innate response activator B cells protect against microbial sepsis. Science 335, 597-601 (2012).
107. Hilgendorf, I. et al. Innate response activator B cells aggravate atherosclerosis by stimulating T helper-1 adaptive immunity. Circulation 129, 1677-1687 (2014).
108. Laffitte, B. A. et al. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc. Natl Acad. Sci. USA 98, 507-512 (2001).
109. Werb, Z. & Chin, J. R. Endotoxin suppresses expression of apoprotein E by mouse macrophages in vivo and in culture. A biochemical and genetic study. J. Biol. Chem. 258, 10642-10648 (1983).
110. Claudel, T. et al. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc. Natl Acad. Sci. USA 98, 2610-2615 (2001).
111. Levin, N. et al. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler. Thromb. Vasc. Biol. 25, 135-142 (2005).
112. -/- mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells. Arterioscler. Thromb. Vasc. Biol. 34, 279-284 (2013).
113. Hong, C. & Tontonoz, P. Liver X receptors in lipid metabolism: opportunities for drug discovery. Nature Rev. Drug Discov. 13, 433-444 (2014).
114. Schmuth, M., Moosbrugger-Martinz, V., Blunder, S. & Dubrac, S. Role of PPAR, LXR, and PXR in epidermal homeostasis and inflammation. Biochim. Biophys. Acta 1841, 463-473 (2014).
115. Yi, T. et al. Oxysterol gradient generation by lymphoid stromal cells guides activated B cell movement during humoral responses. Immunity 37, 535-548 (2012).
116. Hannedouche, S. et al. Oxysterols direct immune cell migration via EBI2. Nature 475, 524-527 (2011).
117. Plump, A. S., Scott, C. J. & Breslow, J. L. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl Acad. Sci. USA 91, 9607-9611 (1994).
118. Badimon, J. J., Badimon, L. & Fuster, V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J. Clin. Invest. 85, 1234-1241 (1990).
119. Rubin, E. M., Krauss, R. M., Spangler, E. A., Verstuyft, J. G. & Clift, S. M. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 353, 265-267 (1991).
120. Nissen, S. E. et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290, 2292-2300 (2003).
121. Tardif, J. C. et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297, 1675-1682 (2007).
122. Khera, A. V. et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364, 127-135 (2011).
123. Cockerill, G. W., Rye, K. A., Gamble, J. R., Vadas, M. A. & Barter, P. J. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 15, 1987-1994 (1995).
124. Yvan-Charvet, L. et al. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler. Thromb. Vasc. Biol. 30, 1430-1438 (2010).
125. Suzuki, M. et al. High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide. Circulation 122, 1919-1927 (2010).
126. De Nardo, D. et al. High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nature Immunol. 15, 152-160 (2014).
127. Gold, E. S. et al. ATF3 protects against atherosclerosis by suppressing 25-hydroxycholesterol-induced lipid body formation. J. Exp. Med. 209, 807-817 (2012).
128. Tardif, J. C. et al. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur. Heart J. http://dx.doi.org/10.1093/eurheartj/ehu171 (2014).
129. Diditchenko, S. et al. Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux. Arterioscler. Thromb. Vasc. Biol. 33, 2202-2211 (2013).
130. Murphy, A. J., Funt, S., Gorman, D., Tall, A. R. & Wang, N. Pegylation of high-density lipoprotein decreases plasma clearance and enhances antiatherogenic activity. Circ. Res. 113, e1-e9 (2013).
131. Nicholls, S. J. et al. ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies. Cardiovasc. Drugs Ther. 26, 181-187 (2012).
132. Picaud, S. et al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc. Natl Acad. Sci. USA 110, 19754-19759 (2013).
133. McLure, K. G. et al. RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist. PLoS ONE 8, e83190 (2013).
134. Halley, P. et al. Regulation of the apolipoprotein gene cluster by a long noncoding RNA. Cell Rep. 6, 222-230 (2014).
135. Watson, C. E. et al. Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J. Lipid Res. 52, 361-373 (2011).
136. Bloedon, L. T. et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J. Lipid Res. 49, 1344-1352 (2008).
137. Moore, K. J., Sheedy, F. J. & Fisher, E. A. Macrophages in atherosclerosis: a dynamic balance. Nature Rev. Immunol. 13, 709-721 (2013).
138. Libby, P., Lichtman, A. H. & Hansson, G. K. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity 38, 1092-1104 (2013).
139. Westerterp, M. et al. ATP-binding cassette transporters, atherosclerosis, and inflammation. Circ. Res. 114, 157-170 (2014).
140. Murphy, A. J. et al. Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis. Nature Med. 19, 586-594 (2013).
141. Swirski, F. K. et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325, 612-616 (2009).
142. Nahrendorf, M. et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J. Exp. Med. 204, 3037-3047 (2007).
143. Dutta, P. et al. Myocardial infarction accelerates atherosclerosis. Nature 487, 325-329 (2012).